Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UO2P
|
|||
| Drug Name |
Avapritinib
|
|||
| Synonyms |
1703793-34-3; UNII-513P80B4YJ; 513P80B4YJ; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; Avapritinib [INN]; BLU-285 (Avapritinib); SCHEMBL16652297; EX-A1366; BCP20175; CS-7577; ACN-051245; HY-101561; (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine
Click to Show/Hide
|
|||
| Indication | Gastrointestinal stromal tumour [ICD-11: 2B5B] | Approved | [1] | |
| Mast cell leukaemia [ICD-11: 2A21.00; ICD-10: C94.3] | Phase 1 | [2] | ||
| Systemic mastocytosis [ICD-11: 2A21.0; ICD-9: 202.6, 757.33] | Phase 1 | [3] | ||
| Company |
Blueprint Medicines Cambridge, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H27FN10
|
|||
| Canonical SMILES |
CC(C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N
|
|||
| InChI |
1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1
|
|||
| InChIKey |
DWYRIWUZIJHQKQ-SANMLTNESA-N
|
|||
| CAS Number |
CAS 1703793-34-3
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.